CURE staff

CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, has selected 

 the winner of the 2020 Extraordinary Healer® Award for Oncology Nursing, which honors exceptional nurses for their efforts in the oncology community.

 has been selected winner of the 2020 The Finest Hour award, which recognizes the selfless achievements of an extraordinary nurse working to provide care during the COVID-19 pandemic.

Santure and Farrat were recognized Sept. 17 during the 2020 Extraordinary Healer® Award for Oncology Nursing virtual celebration in conjunction with the ONS Bridge™ Virtual Conference. Rita Wilson, multitalented actress, producer, singer/songwriter and breast cancer survivor served as the event’s keynote speaker.

“We are pleased to give Christie and Elizabeth these awards for their tremendous dedication, expertise and helpfulness in caring for patients,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences™, parent company of CURE Media Group. “They have gone above and beyond to make a difference in the lives of patients, their families and their caregivers, and we cannot thank them enough for all that they do every day.”

Santure is an infusion nurse at UPMC Hillman Cancer Center in Pittsburgh, where she launched a Caring for the Caregiver program, a support group for those who are caring for someone undergoing cancer treatment. She offers sessions twice a month at the cancer center and is working with leadership to start the program at other UPMC locations. Santure started as a candy-striper and has been a nurse for 40 years.

Farrat works as a perioperative nurse liaison in the operating room at Memorial Sloan Kettering (MSK) Cancer Center in New York City. Previously, Farrat worked in the intensive care unit (ICU) at MSK for 10 years, where she helped design and facilitate the ICU orientation trajectory, ICU preceptor expectations and workflow. In addition, she helped create an ICU Teaching the Teacher Continuing Education Program for ICU preceptors. During the COVID-19 surge, Farrat was redeployed to the ICU to care for patients who were critically ill with the virus. She helped implement real-time, critical-care training of step-down registered nurses so they were able to provide ICU care.

“Bristol Myers Squibb is proud to continue its sponsorship of the Extraordinary Healer® Award that this year recognizes the incredible dedication and passion that Christie and Elizabeth share with their patients every day,” said Brent Pfeiffenberger, senior vice president and head of U.S. Oncology, Bristol Myers Squibb. “Nurses play a critical role in a patient’s cancer journey, which often extends beyond diagnosis and treatment to providing support and guidance through every challenge and triumph experienced during care. Thank you to all of our nurses, and especially to Christie and Elizabeth, for your unwavering commitment to patients and for serving as an inspiration to us all.”

“Janssen Oncology is honored to continue our support for the Extraordinary Healer® Award, recognizing nurses who are exemplary in their dedication to improving the lives of their patients every day and particularly as we continue to navigate the uncertainties of the COVID-19 pandemic. We remain inspired by their compassion and join the oncology community in recognizing nurses as a critical part – and often the heart – of the journey for any patient,” said Serge Messerlian, president of Janssen Oncology.

Founded in 2007, the Extraordinary Healer® Award for Oncology Nursing has received hundreds of nominations, and it continues to grow each year. The men and women honored by the award during the last 14 years have been nominated by adults and children representing a variety of cancer centers and hospitals across the country. The other 2020 finalists were 

Vicki Dodson, B.S.N., RN, OCN; and Maria Rodriguez, B.S.N., RN.

For more information on how to nominate an oncology nurse for the 2021 Extraordinary Healer® Award for Oncology Nursing, click 

This event is supported by Bristol Myers Squibb and Janssen Oncology: Pharmaceutical Companies of Johnson & Johnson.

CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry-leading website, 

; innovative video programs, such as “CURE Connections®” live events; and 

® magazine, which reaches more than 1 million readers, as well as the dynamic website for oncology nurses, 

™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at 

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol Myers Squibb Company. In certain countries outside the United States, due to local laws, Celgene and Juno Therapeutics are referred to as Celgene, a Bristol Myers Squibb company, and Juno Therapeutics, a Bristol Myers Squibb company.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Articles

Santure was recognized for her compassionate care for patients and their families; also during virtual ceremony, Elizabeth Farrat named 2020 The Finest Hour award winner.



CURE Media Group Names Christie Santure, B.S.N., RN, OCN, Winner of 2020 Extraordinary Healer® Award for Oncology Nursing

better-informedIn support of National Prostate Cancer Awareness Month, the CURE® Speaking Out video series has revealed a five-episode discussion titled, 

 professor of medicine and director of the division of hematology, oncology and transplantation at the University of Minnesota. Ryan is a member of the ZERO - The End of Prostate Cancer medical advisory board.

“We are honored to have Dr. Charles Ryan partake in our educational series to increase awareness of and help prevent prostate cancer,” said Mike Hennessy Jr., president, and CEO of MJH Life Sciences™, parent company of CURE Media Group. “These expert video clips are an incredible resource, and we encourage our viewers and readers to share with patients, caregivers and survivors.”

During this series, Ryan discusses a variety of topics related to prostate cancer. In the first episode, he provides an overview of the basics of the disease, including signs, symptoms, and risk factors. In the following episodes, Ryan reviews the differences between genetics and genomics in prostate cancer, treatment options for men with advanced disease and how the COVID-19 pandemic has affected individuals, while also addressing racial disparities associated with prostate cancer.

“I am delighted to work with CURE and ZERO to address some of the common concerns faced by men who are recently diagnosed with prostate cancer as well as those who have been receiving treatment for many years,” said Ryan. “My hope is that those who listen to this series are able to be better informed patients with their doctors, have a deeper understanding of their own unique set of situations with this disease, and to alleviate some of the natural and expected anxieties of being a cancer patient.”

Jamie Bearse, CEO of ZERO added, “By providing educational resources and expert insights, patients can become better equipped in making informed decisions regarding their treatment and cancer care. Tools like this video series help empower patients to be their own best advocates."

 is a video platform designed to offer patients, caregivers, and advocates as much information as possible for their cancer journey. In parallel with its print columns, CURE™ provides patients and caregivers with firsthand information from experts in the field. Throughout each video series, CURE® works with leading cancer advocacy groups to offer advice and assistance to individuals across various cancer types, as well as their caregivers, advocates, and health care professionals, to provide cancer updates, research, and education.

To view the complete video series, click 

CURE Media Group is the leading resource for cancer updates, research and education. It features a full suite of media products, including the industry-leading website, 

; innovative video programs, such as “CURE Connections®,” a series of widely attended live events; 

® magazine, which reaches more than 1 million readers; and the dynamic website for oncology nurses, 

™, the largest privately held, independent, full-service medical media company in North America, dedicated to delivering trusted health care news across multiple channels.

Charles J. Ryan, M.D., internationally recognized for his research on prostate cancer, discusses risk factors, treatments and racial disparities associated with the disease.



CURE® Speaking Out Launches Video Series in Recognition of National Prostate Cancer Awareness Month

There have been several updates in the field of metastatic breast cancer over the last several weeks.

® looks back at some of the latest news and updates affecting patients with metastatic breast cancer.

, especially among women aged 45 years to 64 years, through lost productivity, according to the results of a productivity cost analysis published in 

The combination of pyrotinib plus Xeloda (capecitabine) 

provides a better progression-free survival (PFS) rate

 than Tykerb (lapatinib) plus Xeloda in patients with HER2-positive metastatic breast cancer (mBC) who were previously treated with Herceptin (trastuzumab) and chemotherapy, according to recent data.

First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy 

 in patients with locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC), according to data presented at the 2020 ASCO Virtual Scientific Program.

The phase 3 Impassion131 study — designed to evaluate the immunotherapy Tecentriq (atezolizumab) in combination with the chemotherapy paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer (TNBC) — 

 of improving progression-free survival, compared with placebo plus paclitaxel.

Recently, updated findings of the phase 2 HER2CLIMB study demonstrated that patients with HER2-positive metastatic breast cancer who developed brain metastases experienced a 52% 

 after receiving the combination of Tukysa (tucatinib), Herceptin (trastuzumab) and capecitabine.

A roundup of the latest news and updates for patients with metastatic breast cancer from CURE®.

The Latest News and Updates in Metastatic Breast Cancer

There have been several updates in the field of prostate cancer over the last several weeks. Here, 

® looks back at some of the latest news and updates affecting patients with the disease.

Family history of prostatic borderline or in situ neoplasia (PBSIN) appears to be as important as invasive prostate cancer (PCa) when it comes to increased risk of disease or death. 

This history should be an essential consideration

 in screening recommendations for prostate cancer and in research, according to study results published in 

While prostate cancer treatment can cause cardiovascular-related side effects, patients can take 

, according to Dr. Neal D. Shore, medical director of the Carolina Urologic Research Center.

Black men with newly diagnosed, castration-resistant prostate cancer (mCRPC) that has metastasized to bone 

do not face an increased risk of skeletal-related events

 (SREs) or overall mortality, according to recent study findings published in 

The risk for a major cardiovascular event 

 in patients who received relugolix compared with the hormone-associated therapy leuprolide.

 on the pivotal phase 3 trial design for VERU-111, a novel androgen-blocking agent being evaluated in metastatic castration-resistant prostate cancer.

A roundup of the latest news and updates for patients with prostate cancer from CURE®.

Author | CURE staff

New content coming soon, please check back later.